This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Anti-psychotic medications are often effective for the positive symptoms of schizophrenia, and allow many patients to lead normal lives. However, many patients suffer from negative symptoms, which include inexpressiveness, deficits in cognitive and emotional skills, and lethargy. To date, the FDA has not approved any drug for the treatment of the negative symptoms of schizophrenia, and from the clinical data available it does not appear as though existing drugs – even new generation drugs – represent a significant improvement in this area. It should be stressed that in addition to the progressive decline in quality of life, the negative symptoms can even hamper psychological and psychiatric treatment, which is often needed in order to complement drug therapy.
As schizophrenia is associated with hypofrontality, repeated activation of prefrontal regions and the deeper reward-related network innervated by the prefrontal cortex, may have long term effects on excitability of these neurons and allow effective treatment of the devastating negative symptoms of schizophrenia. In addition, many schizophrenic patients experience auditory hallucinations.
BrainsWay’s* treatment offers an effective*, safe
and non-invasive treatment that uses Deep Transcranial Magnetic Stimulation (TMS) to treat schizophrenia. The treatment performs magnetic stimulation of brain structures and networks responsible for the negative symptoms of schizophrenia and brings significant improvement to patients.
It is an outpatient procedure and does not require hospitalization or anesthesia, is generally well tolerated and entails minimal systemic side effects*.
BrainsWay’s treatment is approved by the CE* and by ANIVISA for treating schizophrenia (negative symptoms).
* Click here for references
IMPORTANT: BrainsWay is at different stages of regulatory approval for different indications in different countries. While the status of our regulatory approvals is generally updated on this website, in order to verify whether BrainsWay is currently approved in your area for the treatment of this indication, please contact us at firstname.lastname@example.org
You are viewing a page that is not intended for persons in the United States, and includes information about treatment applications that HAVE NOT BEEN CLEARED by the FDA for safety and efficacy.